Skip to main content
Advertisement
Advertisement
ORMP
ORMP logo
Oramed Pharmaceuticals Inc.
3.69
USD
Sponsored
-0.20
-5.14%
Nov 19, 15:59 UTC -5
Closed
exchange

After-Market

3.85

+0.16
+4.34%

Oramed Pharmaceuticals Inc. (ORMP) Earnings

ORMP Earnings Reports

Positive Surprise Ratio

ORMP beat 13 of 18 last estimates.

72%

Next Report

Date of Next Report
Mar 24, 2027
Estimate for Q4 26 (Revenue/ EPS)
--
/
$0.37
Implied change from Q3 26 (Revenue/ EPS)
--
/
-13.95%
Implied change from Q4 25 (Revenue/ EPS)
--
/
+54.17%

Oramed Pharmaceuticals Inc. earnings per share and revenue

On Nov 12, 2026, ORMP reported earnings of 0.43 USD per share (EPS) for Q3 26, missing the estimate of 0.43 USD, resulting in a -1.96% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.94% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.37 USD, with revenue projected to reach -- USD, implying an decrease of -13.95% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Omeros Corporation
Report Date
Nov 16, 2026 For Q3 26
Estimate
$0.03
Actual
$0.06
Surprise
+96.08%
logo
Sanara MedTech Inc. Common Stock
Report Date
Nov 12, 2026 For Q3 26
Estimate
$0.06
Actual
-$0.16
Surprise
-361.44%
logo
MacroGenics, Inc.
Report Date
Nov 12, 2026 For Q3 26
Estimate
-$0.06
Actual
-$0.32
Surprise
-367.15%
logo
Glass House Brands Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.04
Actual
-$0.14
Surprise
-191.06%
logo
Immucell Corp
Report Date
Nov 12, 2026 For Q3 26
Estimate
-
Actual
$0.10
Surprise
-
logo
FitLife Brands, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
$0.24
Actual
$0.16
Surprise
-34.64%
logo
Rockwell Medical, Inc. (DE) Common Stock
Report Date
Nov 12, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.37
Surprise
-179.03%
logo
Modular Medical, Inc. Common Stock
Report Date
Nov 16, 2026 For Q2 26
Estimate
-$0.10
Actual
-$0.90
Surprise
-782.35%
logo
Cytosorbents Corp.
Report Date
Nov 12, 2026 For Q3 26
Estimate
-$0.91
Actual
-$0.57
Surprise
+36.82%
logo
Agape ATP Corporation Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-
Actual
-$0.08
Surprise
-
FAQ
For Q3 2026, Oramed Pharmaceuticals Inc. reported EPS of $0.43, missing estimates by -1.96%, and revenue of $0.00, 0% as expectations.
The stock price moved down -7.94%, changed from $4.03 before the earnings release to $3.71 the day after.
The next earning report is scheduled for Mar 24, 2027.
Based on -- analysts, Oramed Pharmaceuticals Inc. is expected to report EPS of $0.37 and revenue of -- for Q4 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement